Nalaganje...
Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugs
HER2-positive breast cancer is an aggressive tumour that affects approximately one in five breast cancer women. Clinical studies have shown that HER2-positive cancer have different characteristics from other mammary tumors: a more rapid progression of the disease, an earlier age of onset (women of c...
Shranjeno v:
Main Authors: | , |
---|---|
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
AboutScience Srl
2018-10-01
|
Serija: | AboutOpen |
Teme: | |
Online dostop: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/135 |
Oznake: |
Označite
Brez oznak, prvi označite!
|